Skip to main content
EXAS logo

EXAS · EXACT SCIENCES CORP

Track EXAS — free
Shares
190.89M

EXACT SCIENCES CORP Earnings Call Transcripts

Every quarterly earnings call for EXACT SCIENCES CORP (EXAS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY25 · Q4
2026-02-13
EXACT SCIENCES CORP Q4 FY2025 Earnings Call
Revenue
$878.38M*
▲ 23.1% YoY
Gross margin
70.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
EXACT SCIENCES CORP Q3 FY2025 Earnings Call
Confident tone Cologuard and Cologuard Plus Performance Precision Oncology and Oncodetect MRD Cancerguard Multi-Cancer Early Detection Launch
Revenue
$850.74M
▲ 20% YoY
Diluted EPS
$-0.10
Gross margin
68.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
EXACT SCIENCES CORP Q2 FY2025 Earnings Call
Confident tone Freenome licensing deal Raised 2025 guidance and long-term targets Blood-based CRC screening setback
Revenue
$811.09M
▲ 16% YoY
Diluted EPS
$-0.01
Gross margin
69.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
EXACT SCIENCES CORP Q1 FY2025 Earnings Call
Confident tone Cologuard Plus launch Commercial execution and growth initiatives Profitability and margin expansion
Revenue
$706.78M
▲ 10.9% YoY
Diluted EPS
$-0.54
Gross margin
70.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
EXACT SCIENCES CORP Q4 FY2024 Earnings Call
Confident tone Cologuard Plus launch and pricing Care gap programs Oncodetect (MRD) launch
Revenue
$713.42M
▲ 10.3% YoY
Diluted EPS
$-4.67
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
EXACT SCIENCES CORP Q3 FY2024 Earnings Call
Positive tone Care gap screening programs Cologuard Plus FDA approval and launch Rescreen opportunity
Revenue
$708.65M
▲ 12.8% YoY
Diluted EPS
$-0.21
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
EXACT SCIENCES CORP Q2 FY2024 Earnings Call
Confident tone Cologuard screening momentum Cologuard Plus product launch Exact Nexus platform and payer partnerships
Revenue
$699.26M
▲ 12.4% YoY
Diluted EPS
$-0.09
Gross margin
69.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
EXACT SCIENCES CORP Q1 FY2024 Earnings Call
Confident tone Cologuard growth and adoption Financial results and guidance Health systems and payers
Revenue
$637.52M
▲ 5.8% YoY
Diluted EPS
$-0.60
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
EXACT SCIENCES CORP Q4 FY2023 Earnings Call
Confident tone Cologuard franchise and screening momentum Precision Oncology and Oncotype DX Pipeline programs (MRD, OncoExTra, OncoLiquid, MCED)
Revenue
$646.88M
▲ 17% YoY
Diluted EPS
$-0.27
Gross margin
70.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
EXACT SCIENCES CORP Q3 FY2023 Earnings Call
Revenue
$628.34M
▲ 20.1% YoY
Diluted EPS
$0.00
Gross margin
69.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
EXACT SCIENCES CORP Q2 FY2023 Earnings Call
Revenue
$622.09M
▲ 19.3% YoY
Diluted EPS
$-0.45
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
EXACT SCIENCES CORP Q1 FY2023 Earnings Call
Revenue
$602.45M
▲ 23.8% YoY
Diluted EPS
$-0.42
Gross margin
70.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
EXACT SCIENCES CORP Q4 FY2022 Earnings Call
Revenue
$553.00M*
▲ 16.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
EXACT SCIENCES CORP Q3 FY2022 Earnings Call
Revenue
$523.07M
▲ 14.6% YoY
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
EXACT SCIENCES CORP Q2 FY2022 Earnings Call
Revenue
$521.64M
▲ 20% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-26
EXACT SCIENCES CORP Q1 FY2022 Earnings Call
Revenue
$486.57M
▲ 21% YoY
Diluted EPS
$-1.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
EXACT SCIENCES CORP Q4 FY2021 Earnings Call
Revenue
$473.81M
▲ 1.6% YoY
Diluted EPS
$-1.28
Gross margin
70.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
EXACT SCIENCES CORP Q3 FY2021 Earnings Call
Revenue
$456.38M
▲ 11.8% YoY
Diluted EPS
$-0.97
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
EXACT SCIENCES CORP Q2 FY2021 Earnings Call
Revenue
$434.82M
▲ 61.7% YoY
Diluted EPS
$-1.03
Gross margin
68.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
EXACT SCIENCES CORP Q1 FY2021 Earnings Call
Revenue
$402.08M
▲ 15.6% YoY
Diluted EPS
$-0.18
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
EXACT SCIENCES CORP Q4 FY2020 Earnings Call
Revenue
$466.34M
▲ 57.8% YoY
Diluted EPS
$-2.67
▼ 594.4% YoY
Gross margin
74.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-27
EXACT SCIENCES CORP Q3 FY2020 Earnings Call
Revenue
$408.36M
▲ 86.6% YoY
Diluted EPS
$-1.35
Gross margin
71.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
EXACT SCIENCES CORP Q2 FY2020 Earnings Call
Revenue
$268.87M
▲ 34.5% YoY
Diluted EPS
$-0.45
Gross margin
63.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-21
EXACT SCIENCES CORP Q1 FY2020 Earnings Call
Revenue
$347.82M
▲ 114.6% YoY
Diluted EPS
$-0.91
Gross margin
70.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-11
EXACT SCIENCES CORP Q4 FY2019 Earnings Call
Revenue
$295.57M
▲ 106.7% YoY
Diluted EPS
$0.54
Gross margin
72.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–25 of 25 earnings calls
Key facts CIK 1124140 CUSIP 30063P105 13F (30d) 42 filings 7 filers Visit website